Treatment of systemic-onset juvenile arthritis with canakinumab

Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Peitz J, Horneff G
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b57406
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:974a3e6cbe3c4fa79506ad41d2b57406
record_format dspace
spelling oai:doaj.org-article:974a3e6cbe3c4fa79506ad41d2b574062021-12-02T02:46:03ZTreatment of systemic-onset juvenile arthritis with canakinumab1179-156Xhttps://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b574062015-02-01T00:00:00Zhttp://www.dovepress.com/treatment-of-systemic-onset-juvenile-arthritis-with-canakinumab-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156X Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis. Keywords: anakinra, canakinumab, interleukin-1, interleukin-6, systemic-onset juvenile idiopathic arthritisPeitz JHorneff GDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2015, Iss default, Pp 23-31 (2015)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the musculoskeletal system
RC925-935
spellingShingle Diseases of the musculoskeletal system
RC925-935
Peitz J
Horneff G
Treatment of systemic-onset juvenile arthritis with canakinumab
description Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis. Keywords: anakinra, canakinumab, interleukin-1, interleukin-6, systemic-onset juvenile idiopathic arthritis
format article
author Peitz J
Horneff G
author_facet Peitz J
Horneff G
author_sort Peitz J
title Treatment of systemic-onset juvenile arthritis with canakinumab
title_short Treatment of systemic-onset juvenile arthritis with canakinumab
title_full Treatment of systemic-onset juvenile arthritis with canakinumab
title_fullStr Treatment of systemic-onset juvenile arthritis with canakinumab
title_full_unstemmed Treatment of systemic-onset juvenile arthritis with canakinumab
title_sort treatment of systemic-onset juvenile arthritis with canakinumab
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/974a3e6cbe3c4fa79506ad41d2b57406
work_keys_str_mv AT peitzj treatmentofsystemiconsetjuvenilearthritiswithcanakinumab
AT horneffg treatmentofsystemiconsetjuvenilearthritiswithcanakinumab
_version_ 1718402179265462272